Literature DB >> 19431172

Pretubulysin, a potent and chemically accessible tubulysin precursor from Angiococcus disciformis.

Angelika Ullrich1, Yi Chai, Dominik Pistorius, Yasser A Elnakady, Jennifer E Herrmann, Kira J Weissman, Uli Kazmaier, Rolf Müller.   

Abstract

Simplify, simplify, simplify! Pretubulysin (structure without the green substituents), a simplified tubulysin was prepared in the laboratory and also found in a natural myxobacterial source. This biosynthetic precursor of the tubulysins is not as active as tubulysins A and D but is still effective in picomolar concentrations against cancer cell lines.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19431172     DOI： 10.1002/anie.200900406

Source DB:  PubMed          Journal:  Angew Chem Int Ed Engl        ISSN： 1433-7851            Impact factor:   15.336


  12 in total

1.  Chemotherapeutic evaluation of a synthetic tubulysin analogue-dendrimer conjugate in c26 tumor bearing mice.

Authors:  William C Floyd; Gopal K Datta; Shinichi Imamura; Heidi M Kieler-Ferguson; Katherine Jerger; Andrew W Patterson; Megan E Fox; Francis C Szoka; Jean M J Fréchet; Jonathan A Ellman
Journal:  ChemMedChem       Date:  2011-01-03       Impact factor: 3.466

2.  Anti-angiogenic effects of the tubulysin precursor pretubulysin and of simplified pretubulysin derivatives.

Authors:  S Rath; J Liebl; R Fürst; A Ullrich; J L Burkhart; U Kazmaier; J Herrmann; Rolf Müller; M Günther; L Schreiner; E Wagner; A M Vollmar; S Zahler
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

3.  An endothelial cell line infected by Kaposi's sarcoma-associated herpes virus (KSHV) allows the investigation of Kaposi's sarcoma and the validation of novel viral inhibitors in vitro and in vivo.

Authors:  Tatyana Dubich; Anna Lieske; Susann Santag; Guillaume Beauclair; Jessica Rückert; Jennifer Herrmann; Jan Gorges; Guntram Büsche; Uli Kazmaier; Hansjörg Hauser; Marc Stadler; Thomas F Schulz; Dagmar Wirth
Journal:  J Mol Med (Berl)       Date:  2019-01-04       Impact factor: 4.599

4.  Pretubulysin: from hypothetical biosynthetic intermediate to potential lead in tumor therapy.

Authors:  Jennifer Herrmann; Yasser A Elnakady; Romina M Wiedmann; Angelika Ullrich; Manfred Rohde; Uli Kazmaier; Angelika M Vollmar; Rolf Müller
Journal:  PLoS One       Date:  2012-05-17       Impact factor: 3.240

5.  2-Hydroxysorangiadenosine: Structure and Biosynthesis of a Myxobacterial Sesquiterpene-Nucleoside.

Authors:  Dorothy A Okoth; Joachim J Hug; Ronald Garcia; Cathrin Spröer; Jörg Overmann; Rolf Müller
Journal:  Molecules       Date:  2020-06-09       Impact factor: 4.411

6.  Combined antitumoral effects of pretubulysin and methotrexate.

Authors:  Sarah Kern; Ines Truebenbach; Miriam Höhn; Jan Gorges; Uli Kazmaier; Stefan Zahler; Angelika M Vollmar; Ernst Wagner
Journal:  Pharmacol Res Perspect       Date:  2019-01-22

7.  Pretubulysin: a new option for the treatment of metastatic cancer.

Authors:  S Braig; R M Wiedmann; J Liebl; M Singer; R Kubisch; L Schreiner; B A Abhari; E Wagner; U Kazmaier; S Fulda; A M Vollmar
Journal:  Cell Death Dis       Date:  2014-01-16       Impact factor: 8.469

8.  Stereoselective access to tubuphenylalanine and tubuvaline: improved Mn-mediated radical additions and assembly of a tubulysin tetrapeptide analog.

Authors:  Gregory K Friestad; Koushik Banerjee; Jean-Charles Marié; Umesh Mali; Lei Yao
Journal:  J Antibiot (Tokyo)       Date:  2016-02-17       Impact factor: 2.649

9.  The pretubulysin-induced exposure of collagen is caused by endothelial cell retraction that results in an increased adhesion and decreased transmigration of tumor cells.

Authors:  Rebecca Schwenk; Tanja Stehning; Iris Bischoff; Angelika Ullrich; Uli Kazmaier; Robert Fürst
Journal:  Oncotarget       Date:  2017-09-08

10.  Synthesis and antitumor activities of 3-substituted-analine derivatives: structure modifications of Tuv part of tubulysins.

Authors:  Mingsha Shao; Xinfa Bai; Xuan Ma; Ning Yan; Lei Yao
Journal:  Chem Cent J       Date:  2018-11-15       Impact factor: 4.215
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.